Stoke Therapeutics, Inc.
NASDAQ:STOK
Overview | Financials
Company Name | Stoke Therapeutics, Inc. |
Symbol | STOK |
Currency | USD |
Price | 13.27 |
Market Cap | 698,636,306 |
Dividend Yield | 0% |
52-week-range | 3.77 - 17.58 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Edward M. Kaye M.D., Ph.D. |
Website | https://www.stoketherapeutics.com |
An error occurred while fetching data.
About Stoke Therapeutics, Inc.
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD